MentalHealthDaily

Anti-CGRP Monoclonal Antibodies to Prevent Chronic Migraine (2023 Review)

Migraine, a primary headache disorder, significantly impacts the quality of life of millions worldwide. In recent years, the focus has shifted toward developing targeted therapies, particularly monoclonal antibodies (mAbs) against the calcitonin-gene-related peptide (CGRP), to prevent chronic migraine attacks. A relatively recent comprehensive network meta-analysis (NMA) evaluated the efficacy and safety of various anti-CGRP mAbs, …

Yoga For Migraines: A Non-Pharmacological Intervention

by GLOOM

Migraines are characterized as intermittently-occurring, painful, throbbing headaches resulting from transient vasodilation of intracranial blood vessels. Estimates suggest that for every 1 million persons in the general population, a total of 3000 migraine attacks will be experienced on a daily basis. Although migraine is among the most common neurological disorders in both men and women, …

Topamax (Topiramate) For Migraines: An Effective Prophylactic?

by GLOOM

Topamax (Topiramate) is an anticonvulsant agent discovered in 1979 by Bruce Maryanoff and Joseph Gardocki while working for McNeil Pharmaceutical (a subsidiary of Johnson & Johnson). When compared to other anticonvulsant agents, Topamax is regarded as unique in that it is pharmacologically classified as a sulfamate-substituted monosaccharide derivative, indicating that its chemical structure is similar …